Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. Uppaluri R, et al. Among authors: jo vy. Clin Cancer Res. 2020 Oct 1;26(19):5140-5152. doi: 10.1158/1078-0432.CCR-20-1695. Epub 2020 Jul 14. Clin Cancer Res. 2020. PMID: 32665297 Free PMC article. Clinical Trial.
Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS. Chau NG, et al. Among authors: jo vy. Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13. Clin Cancer Res. 2016. PMID: 26763254
Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer.
Rabinowits G, Bowden M, Flores LM, Verselis S, Vergara V, Jo VY, Chau N, Lorch J, Hammerman PS, Thomas T, Goguen LA, Annino D, Schoenfeld JD, Margalit DN, Tishler RB, Haddad RI. Rabinowits G, et al. Among authors: jo vy. Front Oncol. 2017 Aug 29;7:191. doi: 10.3389/fonc.2017.00191. eCollection 2017. Front Oncol. 2017. PMID: 28900608 Free PMC article.
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN. Schoenfeld JD, et al. Among authors: jo vy. Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):137-145. doi: 10.1016/j.ijrobp.2018.05.002. Epub 2018 Jun 29. Int J Radiat Oncol Biol Phys. 2018. PMID: 29960819
The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Hanna GJ, Bae JE, Lorch JH, Haddad RI, Jo VY, Schoenfeld JD, Margalit DN, Tishler RB, Goguen LA, Annino DJ Jr, Chau NG. Hanna GJ, et al. Among authors: jo vy. Oncologist. 2020 Jul;25(7):598-608. doi: 10.1634/theoncologist.2019-0841. Epub 2020 Apr 20. Oncologist. 2020. PMID: 32310325 Free PMC article.
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI. Schoenfeld JD, et al. Among authors: jo vy. JAMA Oncol. 2020 Oct 1;6(10):1563-1570. doi: 10.1001/jamaoncol.2020.2955. JAMA Oncol. 2020. PMID: 32852531 Free PMC article. Clinical Trial.
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR. Uppaluri R, et al. Among authors: jo vy. Clin Cancer Res. 2021 Jan 1;27(1):357. doi: 10.1158/1078-0432.CCR-20-4484. Clin Cancer Res. 2021. PMID: 33397681 No abstract available.
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ Jr, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Hanna GJ, et al. Among authors: jo vy. Clin Cancer Res. 2022 Feb 1;28(3):468-478. doi: 10.1158/1078-0432.CCR-21-2635. Epub 2021 Oct 19. Clin Cancer Res. 2022. PMID: 34667025 Free PMC article. Clinical Trial.
116 results